Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Combination Therapy Is More Effective in Stopping Tumor Growth

By LabMedica International staff writers
Posted on 18 Nov 2008
Cancer researchers have found that treating tumors to inhibit the activity of vascular endothelial growth factor (VEGF) to prevent development of new blood vessels is less effective than combining antiangiogenesis treatment with classical chemotherapy.

Investigators at the University of California, San Diego (La Jolla, CA, USA) worked with a line of mice that had been genetically engineered to lack the gene for VEGF. More...
These animals served as a model emulating the results of antiangiogenesis treatment. The absence of VEGF activity made it easier to study the effects of another growth factor, platelet-derived growth factor (PDGF).

Results published in two papers published in the November 9, 2008, online edition of the journal Nature revealed that VEGF in large quantities, as often found in tumor cells, acted to inhibit the activity of PDGF. This prevented PDGF from activating cells called pericytes that surround and stabilize blood vessels, explaining why tumor blood vessels are often immature and poorly functional.

Inhibition of VEGF promotes PDGF activity, which in turn allows tumor blood vessels to mature. Initially this stimulates growth of the tumor, but increased blood flow then facilitates the transport of chemotherapeutic agents into the tumor.

"We have discovered that when antiangiogenesis drugs are used to lower the level of VEGF within a tumor, it is not so much a reduction in the endothelial cells and losing blood vessels as it is an activation of the tumor blood vessels supporting cells,” explained senior author Dr. David Cheresh, professor of pathology at the University of California, San Diego. "This enables vessels to mature, providing a conduit for better drug delivery to the tumor. While the tumors initially get larger, they are significantly more sensitive to chemotherapeutic drugs. It means that chemotherapy could be timed appropriately. We could first stabilize the blood vessels, and then come in with chemotherapy drugs that are able to treat the cancer.”

"It is not just about the therapy, but also what the host does in response to the cancer that makes a difference whether a tumor lives or dies, and if it is susceptible to a drug or not. We can change the host response to the cancer, which is otherwise resistant, and make the vessels more mature, temporarily increasing blood flow to the cancer. We may be giving the right drugs, but we may not be giving them in the right order. We are just beginning to understand how it works,” said Dr. Cheresh.

Related Links:

University of California, San Diego


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.